Antiangiogenic therapy for high-grade glioma
- PMID: 25242542
- DOI: 10.1002/14651858.CD008218.pub3
Antiangiogenic therapy for high-grade glioma
Update in
-
Anti-angiogenic therapy for high-grade glioma.Cochrane Database Syst Rev. 2018 Nov 22;11(11):CD008218. doi: 10.1002/14651858.CD008218.pub4. Cochrane Database Syst Rev. 2018. PMID: 30480778 Free PMC article.
Abstract
Background: The most common primary brain tumours in adults are gliomas. Gliomas span a spectrum from low to high-grade and are graded pathologically on a scale of one to four according to the World Health Organization (WHO) classification. High-grade glioma (HGG) carries a poor prognosis. Grade IV glioma is known as glioblastoma (GBM) and carries a median survival in treated patients of about 15 months. GBMs are rich in blood vessels (i.e. highly vascular) and in a protein known as vascular endothelial growth factor (VEGF), which promotes new blood vessel formation (the process of angiogenesis). Antiangiogenic agents inhibit the process of new blood vessel formation and promote regression of existing vessels. Several antiangiogenic agents have been investigated in clinical trials in newly diagnosed and recurrent HGG, showing promising preliminary results. This review was undertaken to report on the benefits and harms associated with the use of antiangiogenic agents in the treatment of HGGs.
Objectives: To evaluate the efficacy and toxicity of antiangiogenic therapy in patients with high-grade glioma. This intervention can be used in two broad groups of patients: those with first diagnosis as part of 'adjuvant' therapy, and those with recurrent or progressive disease. Comparisons will include the following.• Treatment with antiangiogenic therapy versus placebo.• Treatment (such as chemotherapy or chemoradiotherapy) with antiangiogenic therapy added versus the same treatment without the addition of antiangiogenic therapy.
Search methods: Searches were conducted to identify published and unpublished Randomised Controlled Trials (RCTs) starting in 2000; the following databases were searched: the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 3, 2014; MEDLINE to April 2014 and EMBASE to April 2014. Proceedings of relevant oncology conferences since 2000 were handsearched.
Selection criteria: RCTs evaluating the use of antiangiogenic therapy versus control treatment without antiangiogenic therapy in the treatment of HGG.
Data collection and analysis: Review authors screened the search results and reviewed the abstracts of potentially relevant articles before retrieving the full text of eligible articles.
Main results: After a comprehensive literature search, seven eligible RCTs were identified (total of 2987 participants). Significant design heterogeneity was noted in the included studies, especially in the response assessment criteria used. All eligible studies were restricted to GBMs, and no eligible studies evaluated other HGGs. Four studies were available only in abstract form. We have reserved an overall assessment of the quality of the evidence until the final study publications are received. The three studies that have been published in full were judged to have low risk of bias. The seven trials of 2987 participants included in this systematic review did not show improvement in OS with the addition of antiangiogenic therapy (pooled hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.86 to 1.02; P value 0.16). However, pooled analysis of PFS from six studies (2847 participants) showed improvement in PFS with the addition of antiangiogenic therapy (HR 0.74, 95% CI 0.68 to 0.81; P value < 0.00001). Bevacizumab was the antiangiogenic therapy more likely to yield favourable results. Pooled HR for PFS for bevacizumab studies (three studies with 1712 participants) was significant at 0.66 (95% CI 0.59 to 0.74; P value < 0.00001), and this was reflected in the lower hazard ratio reported in the pooled analysis of bevacizumab studies compared with the overall analysis. Nevertheless, this finding was not significant for OS (HR 0.92, 95% CI 0.83 to 1.02; P value 0.12). Similar to trials of antiangiogenic therapies in other solid tumours, adverse events related to this class of therapy included hypertension and proteinuria, poor wound healing and the potential for thromboembolic events, although generally, the occurrence of grade 3 events of this kind was low (< 14.1%), consistent with reported findings of studies of bevacizumab in other tumours.
Authors' conclusions: In patients with newly diagnosed GBM, the use of antiangiogenic therapy does not improve survival, despite evidence of improved progression-free survival. Thus at this time, evidence is insufficient to support the use of antiangiogenic therapy in patients with newly diagnosed GBM on the basis of effects on survival.Bevacizumab may confer a progression-free survival benefit in GBM; however evidence in favour of using other antiangiogenic therapies in recurrent GBM is insufficient.Although bevacizumab appears to prolong progression-free survival in newly diagnosed and recurrent GBM, the impact of this on quality of life remains unclear.Adequately powered, randomised, placebo-controlled studies of bevacizumab in recurrent GBM (or HGG) are needed.Not addressed here is whether subsets of patients with newly diagnosed GBM may benefit from antiangiogenic therapies and whether these therapies are useful in other high-grade glioma histologies.
Similar articles
-
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2. Cochrane Database Syst Rev. 2021. PMID: 34559423 Free PMC article. Review.
-
Anti-angiogenic therapy for high-grade glioma.Cochrane Database Syst Rev. 2018 Nov 22;11(11):CD008218. doi: 10.1002/14651858.CD008218.pub4. Cochrane Database Syst Rev. 2018. PMID: 30480778 Free PMC article.
-
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.Cochrane Database Syst Rev. 2017 Jul 26;7(7):CD011773. doi: 10.1002/14651858.CD011773.pub2. Cochrane Database Syst Rev. 2017. PMID: 28744879 Free PMC article. Review.
-
Temozolomide for high grade glioma.Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD007415. doi: 10.1002/14651858.CD007415.pub2. Cochrane Database Syst Rev. 2013. PMID: 23633341 Free PMC article. Review.
-
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008941. doi: 10.1002/14651858.CD008941.pub2. Cochrane Database Syst Rev. 2012. PMID: 22786517 Review.
Cited by
-
Prognostic risk of immune-associated signature in the microenvironment of brain gliomas.Front Genet. 2023 Oct 6;14:1208651. doi: 10.3389/fgene.2023.1208651. eCollection 2023. Front Genet. 2023. PMID: 37867596 Free PMC article.
-
CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review.Curr Issues Mol Biol. 2023 Jun 22;45(7):5276-5292. doi: 10.3390/cimb45070335. Curr Issues Mol Biol. 2023. PMID: 37504251 Free PMC article. Review.
-
Scale-free correlations and potential criticality in weakly ordered populations of brain cancer cells.Sci Adv. 2023 Jun 28;9(26):eadf7170. doi: 10.1126/sciadv.adf7170. Epub 2023 Jun 28. Sci Adv. 2023. PMID: 37379380 Free PMC article.
-
Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma.Front Neurol. 2023 May 25;14:1191226. doi: 10.3389/fneur.2023.1191226. eCollection 2023. Front Neurol. 2023. PMID: 37305747 Free PMC article.
-
PSMA Expression Correlates with Improved Overall Survival and VEGF Expression in Glioblastoma.Biomedicines. 2023 Apr 11;11(4):1148. doi: 10.3390/biomedicines11041148. Biomedicines. 2023. PMID: 37189766 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous